ImmunityBio’s Soon-Shiong mischaracterized talks with FDA over cancer drug, sources say

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Last year, the Food and Drug Administration refused to consider an application from ImmunityBio to broaden the approved use of Anktiva, its bladder cancer drug, because clinical data were inconclusive and the request breached the agency’s regulatory guidelines. 

Later, when ImmunityBio Chairman Patrick Soon-Shiong publicly criticized the FDA for its decision, he mischaracterized the outcome of a face-to-face meeting he had with FDA officials to discuss Anktiva’s development plans.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In